LONDON--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented ...
Edwards Lifesciences, Inc. EW presented results from two large, real-world studies based on TVT Registry data that demonstrated continued excellent outcomes for patients treated with the Edwards ...
Edwards Lifesciences EW has announced one-year, real-world data on its SAPIEN 3 Ultra RESILIA valve at the PCR London Valves 2024. These data add to the extensive body of evidence on the company’s ...
August 18, 2010 (Montreal, Quebec and Leicester, United Kingdom) — The best way to ensure that a patient who meets criteria for undergoing transcatheter aortic-valve replacement actually ends up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results